Congenital Disorders of Ganglioside Biosynthesis

T. August Li, Ronald Lee Schnaar

Research output: Contribution to journalArticle

Abstract

Gangliosides are expressed on all vertebrate cells and tissues, but are particularly abundant in the mammalian brain, where they constitute major cell-surface determinants on all nerve cells. The same four ganglioside structures, GM1, GD1a, GD1b, and GT1b, constitute the great majority of brain gangliosides in all mammals. Biosynthesis of these major brain gangliosides starts with addition of glucose to the ceramide lipid carrier followed by stepwise addition of up to six additional monosaccharides. This primarily involves the sequential action of seven glycosyltransferases, many of which appear to act specifically on glycolipid (rather than glycoprotein) acceptors. Congenital human disorders of ganglioside biosynthesis are exceedingly rare, but provide a glimpse into the functions of these major nerve cell surface components. To date, less than 100 individuals from 36 family pedigrees have been confirmed to carry deleterious mutations in ganglioside biosynthetic genes. Mutations in ST3GAL5 (coding GM3 synthase) were discovered as the basis for severe congenital infantile seizures, whereas mutations in B4GALNT1 (coding GM2/GD2 synthase) are the basis of hereditary spastic paraplegia accompanied by intellectual disability. In this review, we compile and summarize the findings of these studies, compare human disorders with mouse genetic models, and reflect on the implications for understanding ganglioside function and dysfunction in the nervous system.

Original languageEnglish (US)
JournalProgress in Molecular Biology and Translational Science
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Gangliosides
(N-acetylneuraminyl)-galactosylglucosylceramide N-acetylgalactosaminyltransferase
Mutation
Brain
Hereditary Spastic Paraplegia
G(M1) Ganglioside
Neurons
Glycosyltransferases
Monosaccharides
Ceramides
Genetic Models
Glycolipids
Cellular Structures
Pedigree
Intellectual Disability
Nervous System
Vertebrates
Mammals
Glycoproteins

Keywords

  • B4GALNT1
  • GM2/GD2 synthase
  • GM3 synthase
  • human genetics
  • intellectual disability
  • linkage analysis
  • seizure
  • spasticity
  • ST3GAL5

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology

Cite this

Congenital Disorders of Ganglioside Biosynthesis. / Li, T. August; Schnaar, Ronald Lee.

In: Progress in Molecular Biology and Translational Science, 01.01.2018.

Research output: Contribution to journalArticle

@article{dd8fdb96d5a24c85bb9ecc6f540434bc,
title = "Congenital Disorders of Ganglioside Biosynthesis",
abstract = "Gangliosides are expressed on all vertebrate cells and tissues, but are particularly abundant in the mammalian brain, where they constitute major cell-surface determinants on all nerve cells. The same four ganglioside structures, GM1, GD1a, GD1b, and GT1b, constitute the great majority of brain gangliosides in all mammals. Biosynthesis of these major brain gangliosides starts with addition of glucose to the ceramide lipid carrier followed by stepwise addition of up to six additional monosaccharides. This primarily involves the sequential action of seven glycosyltransferases, many of which appear to act specifically on glycolipid (rather than glycoprotein) acceptors. Congenital human disorders of ganglioside biosynthesis are exceedingly rare, but provide a glimpse into the functions of these major nerve cell surface components. To date, less than 100 individuals from 36 family pedigrees have been confirmed to carry deleterious mutations in ganglioside biosynthetic genes. Mutations in ST3GAL5 (coding GM3 synthase) were discovered as the basis for severe congenital infantile seizures, whereas mutations in B4GALNT1 (coding GM2/GD2 synthase) are the basis of hereditary spastic paraplegia accompanied by intellectual disability. In this review, we compile and summarize the findings of these studies, compare human disorders with mouse genetic models, and reflect on the implications for understanding ganglioside function and dysfunction in the nervous system.",
keywords = "B4GALNT1, GM2/GD2 synthase, GM3 synthase, human genetics, intellectual disability, linkage analysis, seizure, spasticity, ST3GAL5",
author = "Li, {T. August} and Schnaar, {Ronald Lee}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/bs.pmbts.2018.01.001",
language = "English (US)",
journal = "Progress in Molecular Biology and Translational Science",
issn = "1877-1173",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Congenital Disorders of Ganglioside Biosynthesis

AU - Li, T. August

AU - Schnaar, Ronald Lee

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Gangliosides are expressed on all vertebrate cells and tissues, but are particularly abundant in the mammalian brain, where they constitute major cell-surface determinants on all nerve cells. The same four ganglioside structures, GM1, GD1a, GD1b, and GT1b, constitute the great majority of brain gangliosides in all mammals. Biosynthesis of these major brain gangliosides starts with addition of glucose to the ceramide lipid carrier followed by stepwise addition of up to six additional monosaccharides. This primarily involves the sequential action of seven glycosyltransferases, many of which appear to act specifically on glycolipid (rather than glycoprotein) acceptors. Congenital human disorders of ganglioside biosynthesis are exceedingly rare, but provide a glimpse into the functions of these major nerve cell surface components. To date, less than 100 individuals from 36 family pedigrees have been confirmed to carry deleterious mutations in ganglioside biosynthetic genes. Mutations in ST3GAL5 (coding GM3 synthase) were discovered as the basis for severe congenital infantile seizures, whereas mutations in B4GALNT1 (coding GM2/GD2 synthase) are the basis of hereditary spastic paraplegia accompanied by intellectual disability. In this review, we compile and summarize the findings of these studies, compare human disorders with mouse genetic models, and reflect on the implications for understanding ganglioside function and dysfunction in the nervous system.

AB - Gangliosides are expressed on all vertebrate cells and tissues, but are particularly abundant in the mammalian brain, where they constitute major cell-surface determinants on all nerve cells. The same four ganglioside structures, GM1, GD1a, GD1b, and GT1b, constitute the great majority of brain gangliosides in all mammals. Biosynthesis of these major brain gangliosides starts with addition of glucose to the ceramide lipid carrier followed by stepwise addition of up to six additional monosaccharides. This primarily involves the sequential action of seven glycosyltransferases, many of which appear to act specifically on glycolipid (rather than glycoprotein) acceptors. Congenital human disorders of ganglioside biosynthesis are exceedingly rare, but provide a glimpse into the functions of these major nerve cell surface components. To date, less than 100 individuals from 36 family pedigrees have been confirmed to carry deleterious mutations in ganglioside biosynthetic genes. Mutations in ST3GAL5 (coding GM3 synthase) were discovered as the basis for severe congenital infantile seizures, whereas mutations in B4GALNT1 (coding GM2/GD2 synthase) are the basis of hereditary spastic paraplegia accompanied by intellectual disability. In this review, we compile and summarize the findings of these studies, compare human disorders with mouse genetic models, and reflect on the implications for understanding ganglioside function and dysfunction in the nervous system.

KW - B4GALNT1

KW - GM2/GD2 synthase

KW - GM3 synthase

KW - human genetics

KW - intellectual disability

KW - linkage analysis

KW - seizure

KW - spasticity

KW - ST3GAL5

UR - http://www.scopus.com/inward/record.url?scp=85044306169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044306169&partnerID=8YFLogxK

U2 - 10.1016/bs.pmbts.2018.01.001

DO - 10.1016/bs.pmbts.2018.01.001

M3 - Article

JO - Progress in Molecular Biology and Translational Science

JF - Progress in Molecular Biology and Translational Science

SN - 1877-1173

ER -